Widespread Substandard Medicines Circulating in Rajasthan, State Drug Controller Suspended

A major crisis is unfolding in Rajasthan, India, with hundreds of drug samples failing quality tests over the past year, raising concerns about public health and prompting the suspension of the state’s drug controller.

Documents reveal that essential medications – including antibiotics like Amoxicillin and Ciprofloxacin, anti-diabetic drugs, painkillers, and even those for heart ailments – have been found to be substandard. In several instances, over 100,000 units of failed batches, such as antibiotics from Medirich Ltd, had already been distributed to the public before test results flagged them. Six batches of antibiotics, three of the steroid Betamethasone, and four batches of anti-allergics like Levocetirizine were among those that failed quality checks. This comes as the nation grapples with recent child deaths linked to contaminated cough syrup, highlighting vulnerabilities in the pharmaceutical supply chain.

The scale of the problem extends beyond simply failing to meet quality standards; some tested medicines were found to be missing key salts, while others were contaminated, including injectable fluids. Rajasthan’s Drug Controller Commissioner, T Shubhmangalam, stated the state will conduct intensive inspections of 65 pharmaceutical manufacturers in the coming days, adding, “We are taking substandard drugs very seriously.” However, officials acknowledge that enforcement has been weak, with few prosecutions following failed drug sample reports, and delays in sending samples for national blacklisting. For more information on drug safety regulations, see the World Health Organization’s guidelines.

Current Drug Controller Ajay Phatak reported 23 counterfeit drugs were found in 2023, 29 in 2024, and three so far this year, with court permission secured to prosecute 16 cases. Experts warn that substandard and counterfeit medications are prevalent across India due to weak enforcement, jurisdictional issues, and outdated laws, as detailed in a recent report by The Pharmaceutical Journal. The suspended Drug Controller, Rajaram Sharma, has been accused of protecting companies under investigation.

Officials say investigations into products from companies caught with fake drugs were often incomplete, and the state government has pledged further action to address the systemic issues.